Key facts
- This page summarizes Paul Edward Walker's Form 4 filing for Trillium Therapeutics Inc..
- 5 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 19 Nov 2021, 14:34.
Paul Edward Walker - 17 Nov 2021 Form 4 Insider Report for Trillium Therapeutics Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 17 Nov 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Nov 2021, 14:34:15 UTC
- Prior SEC filing
- 19 Oct 2021
- Next SEC filing
- 27 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sasha Keough, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Paul Edward Walker filed Form 4 for Trillium Therapeutics Inc. on 19 Nov 2021.
Change
- Previous filing in this sequence was filed on 19 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRIL
transaction
Common Shares
Disposed to Issuer
- Transaction value
- $0
- Shares
- -5,736,363
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Nov 2021
- Ownership
- See Note 2
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRIL
transaction
Derivative
Warrant to Purchase Common Shares
Disposed to Issuer
- Transaction value
- $0
- Shares
- -850,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Nov 2021
- Ownership
- See Note 2
- Underlying class
- Common Shares
- Underlying amount
- 850,000
- Exercise price
- $0.9600
- Footnotes
- F3
TRIL
transaction
Derivative
Series II Non-Voting Convertible First Preferred Shares
Disposed to Issuer
- Transaction value
- $0
- Shares
- -6,750,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Nov 2021
- Ownership
- See Note 2
- Underlying class
- Common Shares
- Underlying amount
- 6,750,000
- Exercise price
- $0.000000
- Footnotes
- F1
TRIL
transaction
Derivative
Warrant to Purchase Series II Preferred Shares
Disposed to Issuer
- Transaction value
- $0
- Shares
- -5,400,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Nov 2021
- Ownership
- See Note 2
- Underlying class
- Series II Non-Voting Convertible First Preferred Shares
- Underlying amount
- 5,400,000
- Exercise price
- $0.9600
- Footnotes
- F3
TRIL
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -40,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 40,000
- Exercise price
- $12.03
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Paul Edward Walker is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
On November 17, 2021, PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby the Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and preferred shares (collectively, "Shares") of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash (the "Consideration").
Footnote F2
The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 is the sole member of Growth Equity Opportunities Fund V, LLC ("GEO V"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by GEO V in which the Reporting Person has no pecuniary interest.
Footnote F3
At the Effective Time, each warrant to purchase Shares (a "Warrant") outstanding immediately prior to the Effective Time was transferred to the Issuer for, at the holder's election: (x) a cash payment equal to the amount by which the Consideration exceeded the per share exercise price such Warrant, or (y) a cash payment equal to the amount by which the Black-Scholes value of such exceeded the per share exercise price of such Warrant.
Footnote F4
At the Effective Time, each option to purchase Shares (an "Option") outstanding immediately prior to the Effective Time was deemed to be assigned and transferred to the Issuer in exchange for a cash payment equal to the amount by which the Consideration exceeded the per share exercise price of such Option.